AdvocacyRSS2 days ago
A patient with von Willebrand disease shares how much they depend on Humate-P, a medication made from donated plasma. The article highlights how plasma donors' generosity directly impacts the lives of people who need plasma-derived treatments to stay healthy and safe.
WHY IT MATTERSPatients relying on plasma-derived therapies like Humate-P depend on a consistent supply of donated plasma — understanding this connection may inspire more people to become plasma donors and help secure treatment availability.
NewsRSS2 days ago
People with bleeding disorders like hemophilia face daily challenges that go beyond medical treatment. Getting dressed requires careful thought about activities planned for the day, since certain movements or pressure on the body can trigger bleeding. This personal essay shows how bleeding disorders affect everyday life decisions that most people never have to consider.
WHY IT MATTERSPeople with bleeding disorders need to plan physical activities carefully to avoid injuries that could cause internal bleeding, making even routine tasks like choosing clothes a strategic health decision.
Clinical trialRSS2 days ago
A new clinical trial has started testing a drug called IKT-001 in people with pulmonary arterial hypertension (PAH), a rare condition where blood vessels in the lungs become narrowed and make it hard for the heart to pump blood. This is a large Phase 3 trial, which is a late-stage test that happens before a drug might be approved. Nearly 500 adults will participate to see if this drug works better than current treatments.
WHY IT MATTERSIf you have PAH and are already on stable treatment, you may be eligible to join the IMPROVE-PAH trial and potentially access IKT-001 before it becomes widely available.
AdvocacyRSS2 days ago
This article uses the excitement of NASA's Artemis II space mission as inspiration to encourage big dreams about finding a cure for pulmonary hypertension, a serious lung disease that affects blood vessels. The author draws a parallel between humanity's ability to reach for the stars and the hope that patients with pulmonary hypertension should have for breakthrough treatments. The piece is motivational rather than reporting on specific medical news or research developments.
WHY IT MATTERSThis article may resonate emotionally with pulmonary hypertension patients by framing their disease journey within a larger narrative of human achievement and possibility, though it does not announce any new treatments, trials, or clinical developments.
ResearchRSS2 days ago
Researchers found that a Parkinson's disease medication called Crexont helped patients spend more time feeling better and less time experiencing symptoms when they switched from other levodopa treatments. The study showed improvements in movement control and daily functioning across different patient groups. This is early-stage research being presented at a medical conference.
WHY IT MATTERSIf you take levodopa for Parkinson's and struggle with 'off' periods when symptoms return between doses, Crexont may offer a way to extend your good symptom control time throughout the day.
NewsRSS2 days ago
A person with pulmonary hypertension (PH), a rare lung disease that makes it hard for the heart to pump blood through the lungs, shares what it was like growing up with this condition. They had to frequently miss school and explain their illness to classmates who asked questions about their absences. This article highlights the social and emotional challenges that young people with chronic rare diseases face alongside their medical treatment.
WHY IT MATTERSPatients with pulmonary hypertension and their families can find validation and community in peer experiences, while healthcare providers gain insight into the psychosocial impact of PH that extends beyond physical symptoms.
Clinical trialRSS2 days ago
A company called Allrock Bio is testing a new oral medication called ROC-101 for pulmonary hypertension (a condition where blood pressure in the lungs becomes dangerously high). This is a Phase 2a trial, which means they're checking if the drug is safe and works well as an add-on treatment. The trial is now enrolling patients across the U.S., Canada, and Europe.
WHY IT MATTERSIf ROC-101 proves effective as an add-on therapy, it could offer pulmonary hypertension patients a new oral option to combine with their existing treatments, potentially improving symptom control.
AdvocacyRSS2 days ago
A patient-led nonprofit called The Speak Foundation has created a network of specialized clinics called LGMD Centers of Excellence to help people with limb-girdle muscular dystrophy (LGMD), a rare muscle disease. This new network aims to solve a major problem: patients with LGMD have had trouble getting consistent care and doctors have struggled to develop new treatments because the patient population is very small and spread out.
WHY IT MATTERSThis coordinated clinic network could help LGMD patients access specialized care in one place and speed up the development of new treatments by making it easier for researchers to find and study patients.
NewsRSS2 days ago
Upsher-Smith Laboratories created two new websites to help people with Duchenne muscular dystrophy (DMD) who are using a medicine called Kymbee. One website is made for parents and caregivers of children with DMD and includes tips for talking to doctors and instructions for starting the treatment.
WHY IT MATTERSIf your child has DMD and is considering or starting Kymbee treatment, these new websites provide free resources to help you understand the medication and communicate with your healthcare team.
AdvocacyRSS2 days ago
Three organizations that work with facioscapulohumeral muscular dystrophy (FSHD) patients are joining together to make clinical trials better. FSHD is a rare muscle disease that causes weakness in the face, shoulders, and upper arms. This partnership wants to improve how these trials are designed so they can test new treatments more effectively.
WHY IT MATTERSBetter-designed clinical trials mean faster progress toward treatments for FSHD, and patient input through the FSHD Society ensures trials are structured in ways that actually work for people living with the disease.
Clinical trialRSS2 days ago
The FDA has approved a clinical trial for a new cell therapy called remestemcel-L-rknd made by Mesoblast. The therapy will be tested in children ages 5-9 who have Duchenne muscular dystrophy (DMD), a serious muscle disease. About 76 children will participate in the trial and receive either the therapy or a placebo while continuing their regular DMD treatments.
WHY IT MATTERSThis trial represents a new treatment approach for DMD in young children who are still in a critical window for muscle development, offering families a potential alternative or complement to existing therapies.
ResearchRSS2 days ago
Scientists found that haloperidol, a medication normally used to treat psychiatric conditions, may help treat spinal muscular atrophy (SMA) by increasing levels of a protein called SMN that is missing or low in SMA patients. In laboratory tests with mouse cells and human patient cells, haloperidol helped nerve cells survive longer, reduced harmful inflammation, and improved movement. This suggests haloperidol could potentially be used alongside or instead of current SMA treatments.
WHY IT MATTERSIf haloperidol proves effective in human trials, SMA patients could potentially benefit from a medication that already exists and is FDA-approved, potentially offering a faster path to treatment than developing entirely new drugs.
ResearchPUBMED3 days ago
Linear interstitial keratitis (LIK) is a very rare eye condition where a thin line of cloudiness forms in the clear part of the eye (the cornea). This study looked at 6 patients with this condition to better understand what it looks like, how doctors can diagnose it, and what treatments work best. The researchers found that the cloudy line usually appears near the edge of the cornea and can be seen clearly with special eye imaging tools.
WHY IT MATTERSThis is the largest study to date on linear interstitial keratitis, providing eye doctors with new guidance on diagnosis and treatment options for a condition that previously had no agreed-upon management approach.
Clinical trialCLINICALTRIALS3 days ago
Researchers are looking for patients with advanced lung cancer (stage III) that cannot be removed with surgery and has unusual genetic mutations. The study will test whether giving patients targeted drugs based on their specific genetic mutation, followed by surgery, works better than standard treatment. About 120 patients will participate in this research.
WHY IT MATTERSIf you have unresectable stage III NSCLC with a rare mutation, this trial offers access to personalized treatment tailored to your specific genetic profile before surgery—an approach not yet widely available outside research settings.
NewsUNITERARE4 days ago
The PAN Foundation's financial assistance program for Fabry disease patients is currently closed and not accepting new applications. Fabry disease is a rare genetic condition where the body can't break down certain fatty substances, causing problems in the heart, kidneys, and nerves. If you need help paying for Fabry disease treatment, you'll need to check back later or explore other assistance programs.
WHY IT MATTERSIf you have Fabry disease and were counting on PAN Foundation's copay assistance or medication support, you'll need to find alternative financial resources immediately since this program is not currently accepting applications.
NewsUNITERARE4 days ago
The PAN Foundation's financial assistance program for sickle cell disease patients is currently closed and not accepting new applications. This program helps patients pay for medications and treatment costs related to sickle cell disease. You can check the PAN Foundation website to find out when the program reopens or to explore other assistance options.
WHY IT MATTERSIf you have sickle cell disease and were counting on PAN Foundation's copay assistance, you'll need to find alternative financial support resources immediately, as this major assistance program is not currently accepting applications.
NewsUNITERARE4 days ago
The PAN Foundation's financial assistance program for phenylketonuria (PKU) — a rare genetic condition where the body can't break down a protein called phenylalanine — is currently closed. This program normally helps patients pay for treatment costs. The fund status changed on April 20, 2026.
WHY IT MATTERSIf you have PKU and were relying on PAN Foundation assistance to afford your medical care or special diet, you need to find alternative financial resources immediately since this program is no longer accepting applications.
NewsUNITERARE4 days ago
The PAN Foundation's financial assistance program for people with Spinal Muscular Atrophy (SMA) is currently closed and not accepting new applications. The PAN Foundation helps patients pay for medications and treatment costs when they can't afford them. You can check the program website to see when it reopens or find other financial help options.
WHY IT MATTERSIf you have SMA and struggle to afford your treatment, knowing this fund is temporarily closed helps you explore alternative financial assistance programs before your medication runs out.
NewsUNITERARE4 days ago
The PAN Foundation's financial assistance program for Gaucher disease patients is currently closed and not accepting new applications. Gaucher disease is a genetic condition where the body can't break down certain fatty substances, causing organ damage. The PAN Foundation helps patients pay for medications and treatment costs when they can't afford them otherwise.
WHY IT MATTERSIf you have Gaucher disease and need help paying for your treatment, you'll need to find alternative financial assistance programs since this major funding source is temporarily unavailable.
NewsUNITERARE4 days ago
The PAN Foundation's financial assistance program for Duchenne muscular dystrophy patients is currently closed and not accepting new applications. This program previously helped patients pay for medications and treatment costs related to this serious muscle disease. You can check the PAN Foundation website to see when the program reopens or explore other financial assistance options.
WHY IT MATTERSIf you have Duchenne muscular dystrophy and need help paying for medications or treatments, you'll need to find alternative financial assistance programs since this particular fund is not currently accepting applications.